Paper Details

  1. Home
  2. Paper Details

Dalfampridine benefits ambulation but not cognition in multiple sclerosis.

Author: BenedictRalph Hb, DrakeAllison, HojnackiDavid, KolbChanna, MotlRobert, PatrickKara, SatchidanandNikhil, SmerbeckA, Weinstock-GuttmanBianca

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study discusses the potential benefits of dalfampridine, an FDA-approved medication for impaired ambulation in multiple sclerosis (MS), for patients with cognitive impairment. Dalfampridine's effects on saltatory conduction and the association between cognitive and motor function suggest that it may be beneficial for cognitive impairment in MS patients.
Paper Details　
Original Abstract of the Article :
Impaired cognition and ambulation are common in multiple sclerosis (MS). Dalfampridine is the first Food and Drug Administration (FDA)-approved medication to treat impaired ambulation in MS. Dalfampridine may benefit patients with cognitive impairment, given its effects on saltatory conduction and t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/1352458518815795

データ提供：米国国立医学図書館（NLM）

Dalfampridine: A New Hope for Ambulation in Multiple Sclerosis

The world of multiple sclerosis (MS) can be a challenging one, often characterized by impaired cognition and ambulation. This research delves into the potential benefits of Dalfampridine, a medication recently approved by the FDA for treating impaired ambulation in MS patients. The study explores the intriguing possibility that Dalfampridine, known for its effects on saltatory conduction, might also help those with cognitive impairment, given the strong association between cognitive and motor function. It's like finding a hidden spring in the desert, a source of potential relief for those struggling with the effects of MS.

Hope for Improved Ambulation and Cognition

The study's findings suggest that Dalfampridine has the potential to improve ambulation in MS patients, offering a glimmer of hope for increased mobility. While the study's results didn't conclusively demonstrate a positive impact on cognition, they do highlight the potential benefits of Dalfampridine in addressing both motor and cognitive deficits. This finding is akin to discovering a new path in the desert, leading to a greater understanding of MS and potential treatment options.

A Step Towards a Brighter Future for MS Patients

The study's findings offer a ray of hope for MS patients, suggesting a potential treatment that could improve their quality of life. However, further research is needed to fully understand the effects of Dalfampridine on cognition. This study underscores the need for continued exploration of the intricate world of MS, seeking better treatments and understanding the complexities of this challenging condition.

Dr.Camel's Conclusion

While the desert of MS research is vast and complex, this study offers a promising oasis. Dalfampridine holds the potential to improve ambulation for MS patients, potentially impacting cognition as well. More research is needed to explore its full potential, but this study offers a beacon of hope for those navigating the challenges of MS.

Date :
  1. Date Completed 2020-11-16
  2. Date Revised 2020-11-16
Further Info :

Pubmed ID

30566030

DOI: Digital Object Identifier

10.1177/1352458518815795

Related Literature

Article Analysis
・Effects of dalfampridine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.